An interventional study of Mobile Game and Mobile Application in Hiv, sponsored by George Washington University. Completed at 1 site in United States. Open to participants aged 13 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by George Washington University · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will aim to assess the acceptability, usability and efficacy of using state-of-the-art video game technology to increase HIV testing among adolescents and young adults (AYA) ages 13-24. AYA often lack awareness of their personal risk of contracting HIV and where to go for testing and care. This lack of awareness has contributed to poor uptake of HIV testing among AYA despite engagement in high risk behaviors. The goal of this project is to harness this strong motivation to play games to increase HIV testing. Previous games for behavior change have yielded early success for increasing target behaviors among their sample populations, yet research on increasing HIV testing among AYA through gaming has been limited. This intervention builds on prior formative work and is designed to offer AYA personally-tailored risk messages and supports their accessibility to HIV testing and prevention services through an innovative gaming approach that is sharable over social media with in-game rewards for sharing the game with peers. The specific aim of this study is to determine the efficacy of a life-simulation game in changing HIV testing, knowledge, and risk behaviors among AYA at risk for HIV.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 309 is above the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →George Washington University is the lead sponsor of 193 studies on the registry; 34 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will engage with an enhanced life-simulation prototype of a playable interactive game to increase HIV testing, risk assessment tool, and HIV and pre-exposure prophylaxis (PrEP) locators embedded within the game.
Other: Mobile Game
Participants will engage with a mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
Other: Mobile Application
An enhanced life-simulation prototype of a playable interactive game to increase HIV testing.
A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information, and information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
HIV Testing
Self-reported HIV testing in the past 6 months
Time frame: assessed at 6 months from enrollment
Number of Participants Intending to Test for HIV
We counted the number of participants who intended to test for HIV after 6 months of follow up
Time frame: assessed at 6 months after enrollment
Mean HIV Knowledge Test Scores for the Two Groups
Mean score on an 18-item HIV Knowledge test for each of the two groups with a score of 0 indicating no knowledge and 18 indicating maximum knowledge.
Time frame: assessed at 6 months post enrollment
PrEP Use/Uptake
whether participant has been prescribed/taken PrEP
Time frame: assessed at 6 months post enrollment
HIV Testing Locator
Number of times participant clicked on HIV testing locator link
Time frame: assessed at 3 months post enrollment
Mean PrEP Knowledge Score for Each of the Two Groups
Mean score on a 13 item PrEP knowledge scale was calculated with possible scores ranging from 0 (no knowledge) to 13 (maximum knowledge)
Time frame: assessed at 6 months post enrollment
Participants were recruited online through social media advertisements, using community fliers, and through peer referral. Recruitment took place between November 2023 and May 2024. Potential participants were able to scan a QR code or click on an advertisement to complete an online screener that assessed their age, gender, sexual behaviors and orientation, state of residence, and availability of a reliable cell phone. Peer referral allowed eligible participants to recruit up to 3 peers
| Milestone | Mobile Game | Mobile Application |
|---|---|---|
| Started | 156 | 153 |
| Completed | 150 | 149 |
| Not completed | 6 | 4 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Did not complete follow up surveys | 4 | 4 |
Self-reported HIV testing in the past 6 months
| Participants | Mobile Game | Mobile Application |
|---|---|---|
| HIV Testing | 32 | 48 |
We counted the number of participants who intended to test for HIV after 6 months of follow up
| number of participants | Mobile Game | Mobile Application |
|---|---|---|
| Number of Participants Intending to Test for HIV | 74 | 85 |
Mean score on an 18-item HIV Knowledge test for each of the two groups with a score of 0 indicating no knowledge and 18 indicating maximum knowledge.
| mean score on a scale | Mobile Game | Mobile Application |
|---|---|---|
| Mean HIV Knowledge Test Scores for the Two Groups | 12.1 ± 2.5 | 11.4 ± 3.0 |
whether participant has been prescribed/taken PrEP
| Participants | Mobile Game | Mobile Application |
|---|---|---|
| PrEP Use/Uptake | 11 | 14 |
Number of times participant clicked on HIV testing locator link
| number of clicks | Mobile Game | Mobile Application |
|---|---|---|
| HIV Testing Locator | 2 (0 to 3) | 0 (0 to 1) |
Mean score on a 13 item PrEP knowledge scale was calculated with possible scores ranging from 0 (no knowledge) to 13 (maximum knowledge)
| mean score on a scale | Mobile Game | Mobile Application |
|---|---|---|
| Mean PrEP Knowledge Score for Each of the Two Groups | 8.3 ± 3.2 | 8.0 ± 3.4 |
Collected over from enrollment until end of follow up at 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mobile Game | 0/150 (0%) | 0/150 (0%) | 0/150 (0%) |
| Mobile Application | 0/149 (0%) | 0/149 (0%) | 0/149 (0%) |
this is the overall number of participants that were eligible, randomized, and downloaded the control or intervention app
| Age, Continuous(years) | Mobile Game | Mobile Application | Total |
|---|---|---|---|
| Mean | 20.7 ± 1.84 | 20.8 ± 1.84 | 20.7 ± 1.84 |
| Sex/Gender, Customized(Participants) | Mobile Game | Mobile Application | Total |
|---|---|---|---|
| male | 54 | 67 | 121 |
| female | 74 | 71 | 145 |
| other gender | 22 | 11 | 33 |
| Race/Ethnicity, Customized(Participants) | Mobile Game | Mobile Application | Total |
|---|---|---|---|
| Hispanic any race | 32 | 24 | 56 |
| Non hispanic Asian | 32 | 27 | 59 |
| non hispanic black | 24 | 34 | 58 |
| non hispanic multiracial | 10 | 6 | 16 |
| non Hispanic white | 51 | 52 | 103 |
| other race | 1 | 3 | 4 |
| Region of Enrollment(Participants) | Mobile Game | Mobile Application | Total |
|---|---|---|---|
| United States | 150 | 149 | 299 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2023 to primary completion in May 2024, 6 months.
Results were first posted in Nov 2026, 2 years 6 months after primary completion.
Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 6 months is below that.
Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Jun 2021 → Nov 2023, primary completion Oct 2024 → May 2024 and completion Oct 2024 → May 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →
George Washington University →